Merck (MRK) Shows Strong Earnings Following M&A Adjustments; Outlook Flat
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $130.77 +2.97%
EPS Growth %: +47.9%
Financial Fact:
Restructuring costs: 545.6M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: +47.9%
Financial Fact:
Restructuring costs: 545.6M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Merck & Co., Inc. (NYSE: MRK) shares are showing some early weakness Thursday following its fourth-quarter results.
Sales at Merck improved 1.7 percent from $12.094 billion during the same quarter last year to $12.294 billion. The number compared with Street views calling for revs of $12.53 billion.
Merck swung into positive territory, reporting net income of $1.512 billion, from a loss of $531 million in the year-ago quarter. The number played-out to earnings of 49 cents per share. Excluding one-time charges related to acquisitions and other items, EPS rose to 97 cents versus expectations of 95 cents.
Leading sales higher was Singular with an 8 percent increase in fourth-quarter revenue. Januvia sales popped 42 percent to $960 million in the period, a strong move for the diabetes drug. Inflammatory disease treatment Remicad posted the most notable decline, however, with sales dropping 28 percent to $511 million in the quarter following the transfer of rights to Johnson & Johnson (NYSE: JNJ).
Looking ahead, Merck sees fiscal 2012 non-GAAP EPS of $3.75 - $3.85 with revs at or near 2011 levels on a constant currency basis. The Street is modeling EPS of $3.83 and revs of $47.62 billion.
The stock last traded at $38.13, down 1.3 percent from Wednesday's close.
Sales at Merck improved 1.7 percent from $12.094 billion during the same quarter last year to $12.294 billion. The number compared with Street views calling for revs of $12.53 billion.
Merck swung into positive territory, reporting net income of $1.512 billion, from a loss of $531 million in the year-ago quarter. The number played-out to earnings of 49 cents per share. Excluding one-time charges related to acquisitions and other items, EPS rose to 97 cents versus expectations of 95 cents.
Leading sales higher was Singular with an 8 percent increase in fourth-quarter revenue. Januvia sales popped 42 percent to $960 million in the period, a strong move for the diabetes drug. Inflammatory disease treatment Remicad posted the most notable decline, however, with sales dropping 28 percent to $511 million in the quarter following the transfer of rights to Johnson & Johnson (NYSE: JNJ).
Looking ahead, Merck sees fiscal 2012 non-GAAP EPS of $3.75 - $3.85 with revs at or near 2011 levels on a constant currency basis. The Street is modeling EPS of $3.83 and revs of $47.62 billion.
The stock last traded at $38.13, down 1.3 percent from Wednesday's close.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Airbus revenue rises, delivers 142 commercial aircraft in Q1
- Inter Parfums (IPAR) PT Lowered to $172 at Piper Sandler
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
